HLHuiyu Li

Huiyu Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huiyu Li has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Dongmei Guo

    Huazhong University of Science and Technology

    3 shared publications
  • Shenghua Jie

    Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China

    3 shared publications
  • Wen Du

    Center for Stem Cell Research and Application, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Road 1277, Wuhan, 430022, PR China

    3 shared publications
  • Fang Zheng

    Huazhong University of Science and Technology

    2 shared publications
  • Jiahua Zhang

    Center for Stem Cell Research and Application, Institute of Hematology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiegang Avenue, 430022, Wuhan, China

    2 shared publications
  • Liqiong Liu

    Center for Stem Cell Research and Application, Institute of Hematology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiegang Avenue, 430022, Wuhan, China

    2 shared publications

Latest Publications

  • HERG1 K+ channels on the leukemic cells mediated angiogenesis in vitro

    by Huiyu Li, Dongmei Guo, Fang Zheng, Kaiwei Liang, Wenying Li, Shenghua Jie

    Human ether-a-go-go-related gene (HERG1) K+ channels are overexpressed in leukemia, which contributes to neoangiogenesis. The purpose of this study was to investigate the role of HERG1 K+ channels on leukemia angiogenesis. We cultured human umbilical vein endothelial cells (HUVECs) in conditioned media, which were derived from leukemic cells with or without E-4031, a HERG1 K+ channel special inhibitor. The HUVECs proliferation was measured using CCK-8 assay and migration by a Trans-well. Endothelial tube formation was investigated using Matrigel. Vascular endothelial growth factor (VEGF) levels were tested by ELISA and VEGF mRNA expression using RT-PCR. Our results revealed that blocking HERG1 K+ channels could inhibit leukemia-induced HUVECs proliferation, migration, and tube formation in vitro. The results suggested that HERG1 K+ channels could increase leukemia angiogenesis. Furthermore, blockage of HERG1 K+ channels could also decrease leukemic cells secreting VEGF and expressing VEGF mRNA. HERG1 K+ channels have a promoting effect on leukemia angiogenesis, and the possible mechanism may be that HERG1 K+ channels enhance VEGF expression. Thus, HERG1 K+ channel is a potential target of antiangiogenesis in leukemia.


  • Close correlation between development of MODS during the initial 72 h of hospitalization and hospital mortality in severe fever with thrombocytopenia syndrome

    by Sheng-Hua Jie, Yan Zhou, Li-Ping Sun, Kai-Wei Liang, Xiao-Ling Yi, Hui-Yu Li

    An emerging infectious disease was identified as severe fever with thrombocytopenia syndrome (SFTS) in central China since late March 2009. We found the patients with SFTS had severe clinical symptoms, and progressed rapidly to multiple organ dysfunction syndrome (MODS) with high fatality rate of 25%–30%. The aim of this study was to assess the significance of risk factors predicting the development of MODS and death in SFTS patients. Consecutive SFTS admissions between May 2009 and September 2011 were analyzed for parameters of organ function during hospitalization using Marshall scoring system for MODS, and platelet counts were recorded on admission and at 24, 48, 72 h and one week after admission. We investigated the kinetics of organ failures and analyzed the association between age, platelet count and development of MODS or death. A total of 92 SFTS patients were enrolled in this study. Among them, 32 patients with dysfunction of over 4 organs were identified, 45% of them died within 72 h, 72% died within 5 days, and 76% died within 7 days after admission. We also found cumulative Marshall score was significantly higher in death patients (11.76±2.05) than in survival patients (4.22±1.98) (PP<0.001). High Marshall score, advanced age and lower platelet counts were the main risk factors for the development of MODS, and those factors could predict mortality in SFTS patients, suggesting prompt treatment and close monitoring of severe complications, especially MODS, are of great importance in saving patients’ lives.


  • Human ether-a-go-go-related gene K+channels regulate shedding of leukemia cell-derived microvesicles

    by Fang Zheng, Juanjuan Li, Wen Du, Ningfang Wang, Huiyu Li, Shiang Huang

    Microvesicles (MVs) are released by various cancer cells, including leukemia cells. They can “hijack” membrane components from their parental cells and exert pleiotropic effects on tumor progression. Human ether-a-go-go-related gene (hERG1) K + channels are highly expressed in cancer cells and appear of exceptional importance in favoring cancer development. Given the attributes of MVs and hERG1 K + channels in disease progression, we investigated the putative relationship between hERG1 K + channels and MVs in leukemia. The protein content of MVs isolated from K562 cell supernatants was significantly higher than that from HL-60 cells. The molecular profile of these MVs showed that in addition to the myeloid lineage antigen (CD11b), MVs contained hERG1 K + channels. Interestingly, inhibition of hERG1 K + channels rapidly reduced MV fractions in supernatants. Furthermore, MVs created positive feedback loops to facilitate leukemogenesis. Upon exposure to MVs, the plasma membrane expression of hERG1 protein was in turn up-regulated, the migration of leukemia cells was significantly increased, and the adhesion of leukemia cells to human umbilical vein endothelial cells (HUVECs) was markedly enhanced. Importantly, hERG1 K + channel inhibitor E-4031 impaired these effects. We conclude that leukemia cell-derived MVs can “hijack” the plasma membrane hERG1 K + channels, which regulate the release of MVs and their biological effects upon leukemia cells.


    • 1 July 2011
      • Vol. 32  (7) , 489-91

    [Recent advances in microvesicles derived from leukemic cells and its relationship with disease progression].

    by Fan Zheng, Hui-Yu Li, Shi-Ang Huang

  • Berberine inhibits angiogenic potential of Hep G2 cell line through VEGF down‐regulation in vitro

    by Shenghua Jie, Huiyu Li, Yuan Tian, Dongmei Guo, Jiang Zhu, Shaoyang Gao, Li Jiang

    Background and Aim: Berberine, an herbal alkaloid, has been reported to have promotion potential of apoptosis and anticancer effect on a variety of human tumor cells. To obtain more specific understanding of those consequences of berberine on hepatocellular carcinoma (HCC) and the tumor microenvironment, we conductedin vitroexperiments to investigate the inhibitory effect of berberine on tumor‐induced angiogenesis using HCC cells and human umbilical vein endothelial cells (HUVECs).Methods: Human umbilical vein endothelial cell growth was quantified with the CCK‐8 cell proliferation assay; cell migration was observed with a Boyden chamber (Transwell, Corning, Lowell, MA, USA), and angiogenesis was assessed by endothelial tube formation in Matrigelin vitro. In addition, VEGF level was determined by ELISA and VEGF mRNA expression by RT‐PCR.Results: Berberine inhibited the capacity of HCC to stimulate HUVEC's proliferation, migration and endothelial tube formation, suggesting that berberine could influence the cross‐talk between the HCC cell and vascular endothelial cells. These results demonstrate berberine's antiangiogenesis property and its clinical potential as an inhibitor of tumor angiogenesis. Subsequently analyses reveal that berberine prevents secretion of VEGF from HCC and down‐regulates VEGF mRNA expression.Conclusion: These findings strongly suggest that berberine is a potential antiangiogenic agent and a promising antitumor drug for HCC.


  • Circulating LTD4 in patients with hepatocellular carcinoma

    by Yan Zhou, Dongmei Guo, Huiyu Li, Shenghua Jie

    Hepatocellular carcinoma (HCC) is a type of inflammation-related cancer that usually follows chronic inflammations. Leukotriene D4 (LTD4) is a potent biologically active arachidonic acid-derived lipid mediator that is intimately involved in inflammations and cancers. Although previous researches found overexpression of LTD4 in several other cancers, the circulating LTD4 level in HCC remains unknown. The aim of this study was to examine concentrations of LTD4 and analyze its roles in HCC. The results showed that remarkably high circulating LTD4 in HCC versus healthy subjects (p < 0.001). The levels of LTD4 were neither associated with parameters expressing tumor burden, such as AFP, nor with inflammation factors AST and γ-GT. In addition, the significant increase of circulating LTD4 levels was obtained in patients with HCC accompanied by chronic hepatitis B (CHB), compared with those patients suffering HCC alone(P < 0.05). Furthermore, although the slightly lower levels of LTD4 were detected in HCC patients with non-metastasis and therapy compared with metastasis and non-therapy, no significant differences were detected. Taken together, the levels of circulating LTD4 are elevated in HCC and it may participate in the pathogenesis of HCC as an inflammatory factor from CHB disease to HCC.


  • HERG K+ channel expression in CD34+/CD38−/CD123high cells and primary leukemia cells and analysis of its regulation in leukemia cells

    by Huiyu Li, Liqiong Liu, Linlin Guo, Jiahua Zhang, Wen Du, Xiaoqing Li, Wei Liu, Xiangjun Chen, Shiang Huang

    The human ether-a-go-go-related (herg) gene encoding K+ channels (HERG) belongs to an evolutionarily conserved multigene family of voltage activated K+ channels. The functional properties of HERG K+ channels are complex and their contribution to the repolarization of the cardiac action potential are well understood. Recent studies revealed that HERG K+ channels are preferentially expressed in different histogenesis of tumor cells. Leukemia is a cancer that originates in the bone marrow hematopoietic stem cells (HSCs). Leukemia stem cells (LSCs) are critical in the perpetuation of the disease. A better understanding of LSCs and molecular biology will allow the design of more effective therapies. We report in this study that herg was expressed in CD34+/CD38−/CD123high LSCs but not expressed in normal bone marrow CD34+/CD38− HSCs. In addtion, herg is also expressed in leukemia cell lines K562 and HL-60 and almost all the primary leukemia cells whereas not in the normal bone marrow cells. In addition, the expression of herg mRNA was not associated with the clinical and cytogenetic feature of leukemia. Moreover, HERG K+ channels can regulate leukemia cells proliferation and cell cycle. These data provide evidence for the oncogenic potential of HERG K+ channels and it may be a novel, potential pharmacological target for leukemia therapy in the future.


  • Expression and fuactional role of HERG1, K+ channels in leukemic cells and leukemic stem cells

    by Huiyu Li, Liqiong Liu, Tiannan Guo, Jiahua Zhang, Xiaoqing Li, Wen Du, Wei Liu, Xiangjun Chen, Shi’ang Huang


    • 1 May 2007
      • Vol. 15  (5) , 392-3

    [Systemic inflammatory response syndrome and related inflammatory mediators in severe viral hepatitis].

    by Sheng-Hua Jie, Hui-Yu Li, Xiang-Zhen Zhu

    • 13 March 2007
      • Vol. 87  (10) , 710-3

    [Role of MG132, a proteasome inhibitor, in inducing expression of costimulatory molecules CD86 in leukemic cells and its effect on allogeneic mixed lymphocyte reaction].

    by Yong-Ming Zhou, Wei Guo, Ke-Ying Xue, Hao Zhou, Yan-Xiang Cheng, Tian-Nan Guo, Hui-Yu Li, Shi-Ang Huang

    To investigate the role of proteasome inhibitors MG132 in the inducing the expression of the costimulatory molecules CD80 and CD86 in leukemia cells and its effect on allogeneic mixed lymphocyte reaction. Acute myelocytic leukemia cells of the line HL-60 and chronic myelocytic leukemia cells of the line K562 were cultured. 7-AAD staining and flow cytometry (FC) were used to examine the viability of the cells. MG132, a proteasome inhibitor, of the concentrations of 2 or 3 micromol/L was added into the culture fluid of HL-60 cells for 24 h and 48 h respectively and then annexin V/7-AAD staining and FC were used to detect the apoptosis of the cells. HL-60 and K562 cells treated with 1 micromol/L MG132 for 24 h and 48 h respectively, anti-CD80 and anti-CD86 antibodies were added, then FC was used to detect the expression of CD80 and CD86. The mRNA expression of CD86 in the HL-60 cells treated with 1 micromol/L MG132 was examined by RT-PCR. HL-60 and K562 cells were treated by 1 micromol/L MG132 for 48 h and then underwent irradiation of 75 Gy Co-60 to kill the cells with their antigenicity preserved. Peripheral blood mononuclear cells (PBMNC) of healthy volunteers, as reactive cells, were isolated and inoculated into the Co-60 treated HL-60 and K532 cells of different concentrations, as stimulating cells, for 5 d, CCK-8, a new agent to detect the cell viability, was added for 4 h, and then the A value of absorbance was measured at the wave length of 450 nm of enzyme labeling instrument. Control groups were set up for all tests. The cell viability rates of the HL-60 cell treated with 1 micromol/L MG132 for 24 h and 48 h were 92.95% and 85.87% respectively. The apoptotic rats of the HL-60 cells treated with MG132 were increased dose- and time-dependently. Before MG132 treatment K562 cells did not express CD86, and the CD86 expression of the HL-60 cells was up-regulated time-dependently (all P < 0.01). The mRNA expression of CD86 in the HL-60 treated with MG132 was up-regulated time-dependently (P < 0.01). CKK8 test showed that the proliferation level of PBMNC gradually increased along with the concentration of HL-60 cells treated with MG132 and reached its peak when the concentration of the HL-60 cells was 1 x 10(5) (P < 0.01). No remarkable proliferation of PBMNC was seen in the K562 groups no matter if the HL-60 cells had been treated with MG132. MG132 induces the expression of costimulatory molecule CD86 in the HL-60 cells, thus improving the proliferation of PBMNC.